Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

Background and Aim Gastroesophageal reflux disease (GERD) is a common disease caused by reflux of gastric contents to the esophagus. Proton‐pump inhibitors (PPIs) are recommended as a first‐line therapy to treat GERD. Recently, a new potassium‐competitive acid blocker, vonoprazan, was launched in Ja...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of gastroenterology and hepatology 2019-08, Vol.34 (8), p.1316-1328
Hauptverfasser:	Miyazaki, Hirota, Igarashi, Ataru, Takeuchi, Toshihisa, Teng, Lida, Uda, Akihito, Deguchi, Hisato, Higuchi, Kazuhide, Tango, Toshiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Bayes Theorem Bayesian analysis Clinical trials Esophagitis Esophagitis, Peptic - diagnosis Esophagitis, Peptic - drug therapy Esophagitis, Peptic - physiopathology Esophagus gastric secretion Gastroesophageal reflux Gastroesophageal Reflux - diagnosis Gastroesophageal Reflux - drug therapy Gastroesophageal Reflux - physiopathology gastroesophagus reflux disease Humans Network Meta-Analysis Omeprazole Patient Selection Proton pump inhibitors Proton Pump Inhibitors - adverse effects Proton Pump Inhibitors - therapeutic use Pyrroles - adverse effects Pyrroles - therapeutic use Randomized Controlled Trials as Topic Remission Induction Severity of Illness Index Sulfonamides - adverse effects Sulfonamides - therapeutic use Time Factors Treatment Outcome Wound Healing - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!